Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant humanized anti-PD-1 mAb vs high-dose interferon in resected mucosal melanoma
CTR20170779Phase 2Active
- Sponsor
- Junshi Biosciences
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant humanized anti-PD-1 monoclonal antibody in mucosal melanoma (MM), sponsored by Junshi Biosciences. Started Aug 2017; status: active.
02
Drugs
recombinant humanized anti-PD-1 monoclonal antibody
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on CTR20170779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170779.